3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
2
Thoracic
1
Plasma cell
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Neoplasm Metastasis
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
547
Pemetrexed
402
Cisplatin
400
Paclitaxel
272
Docetaxel
255
Gemcitabine
218
pembrolizumab
190
Bevacizumab
190
Erlotinib Hydrochloride
184
Radiotherapy
179
Etoposide
147
durvalumab
140
Nivolumab
134
Drug Therapy
127
osimertinib
106
atezolizumab
92
Gefitinib
74
Radiosurgery
71
anlotinib
69
Vinorelbine
68
tislelizumab
52
Irinotecan
51
Ipilimumab
50
130-nm albumin-bound paclitaxel
49
Taxes
48
Surgical Procedures, Operative
46
Cetuximab
46
sintilimab
45
Albumin-Bound Paclitaxel
45
apatinib
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Water
×
Thoracic
×
Clear all
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts